161 related articles for article (PubMed ID: 34983459)
1. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
3. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
[TBL] [Abstract][Full Text] [Related]
4. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
Rusthoven CG; Lanning RM; Jones BL; Amini A; Koshy M; Sher DJ; Bowles DW; McDermott JD; Jimeno A; Karam SD
Radiother Oncol; 2017 Jul; 124(1):139-146. PubMed ID: 28433411
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis.
Nong S; Pan X; Chen K; Li Y; Zhu X
Med Sci Monit; 2020 Jun; 26():e922244. PubMed ID: 32541642
[TBL] [Abstract][Full Text] [Related]
6. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
[TBL] [Abstract][Full Text] [Related]
8. Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study.
Zheng SH; Wang YT; Liu SR; Huang ZL; Wang GN; Lin JT; Ding SR; Chen C; Xia YF
Cancer Cell Int; 2022 Jan; 22(1):36. PubMed ID: 35073926
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
10. First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for
Yang ZC; Liu T; Chen YZ; Guo CY; Liu LT; Liu SL; Chen QY; Mai HQ; Guo SS
Cancer Control; 2022; 29():10732748221124868. PubMed ID: 36047451
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Patterns and Prognosis of de novo Metastatic Nasopharyngeal Carcinoma in the United States.
Xu Y; Huang T; Mao M; Zhai J; Chen J
Laryngoscope; 2021 Apr; 131(4):E1130-E1138. PubMed ID: 32833262
[TBL] [Abstract][Full Text] [Related]
12. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Liu GY; Li WZ; Peng KQ; Lv X; Ke LR; Wu YS; Wang DL; Liang H; Liu KY; Lv SH; Guo X; Xiang YQ; Xia WX
Cancer Med; 2020 Feb; 9(3):920-930. PubMed ID: 31834990
[TBL] [Abstract][Full Text] [Related]
14. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
16. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.
Xu H; Lu L; Lu T; Xu Y; Zong J; Huang C; Lin F; Zheng Y; Lin C; Lin S; Qiu S; Pan J; Lin S; Guo Q
Head Neck; 2021 Sep; 43(9):2602-2610. PubMed ID: 33904617
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
18. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Du C; Ni M; Jiang J; Kong F; Zhai R; Lv Y; Hu C; Ying H
Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):3947-3956. PubMed ID: 34981158
[TBL] [Abstract][Full Text] [Related]
19. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.
Goshtasbi K; Lehrich BM; Birkenbeuel JL; Abiri A; Harris JP; Kuan EC
Otolaryngol Head Neck Surg; 2021 Jul; 165(1):93-103. PubMed ID: 33231508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
